Mindray Announces Second Quarter 2015 Financial Results

Aug 10, 2015, 17:24 ET from Mindray Medical International Limited

SHENZHEN, China, Aug. 10, 2015 /PRNewswire/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2015.

Highlights for Second Quarter 2015

  • Net revenues reached $336.8 million, up from $334.5 million a year ago.
    • China net revenues were $153.9 million, representing 45.7% of the company's total net revenues.
    • International net revenues totaled $183.0 million.
  • Reagent net revenues grew more than 20% year-over-year. Reagents contributed 48.8% to the IVD segment, up from 42.9% in the same period last year.
  • Launched four products during the quarter, including a mid-end biochemistry analyzer, a mid-to-low-end hematology analyzer, a mid-end glycohemoglobin analyzer, and a mid-to-low-end color ultrasound.
  • In July, Mindray completed the acquisition of the remaining stake in Wuhan Dragonbio and now owns the whole company.

"In the second quarter, the tough operating environment weighed on our financial results. Demand in our major markets remained sluggish and we continued to experience currency headwinds and intensifying competition," commented Mr. Li Xiting, Mindray's Executive Chairman, President and Co-Chief Executive Officer. "However, we are encouraged by the consistent strong growth of our reagent sales. Our R&D productivity also remained strong, with the introduction of four new products during the second quarter."

SUMMARY – Second quarter 2015

(in $ millions, except per-share data)

Three Months Ended

June 30

2015

2014

% chg

Net Revenues

336.8

334.5

0.7%

Net Revenues Generated in China

153.9

152.5

0.9%

Net Revenues Generated in International Markets

183.0

182.0

0.5%

Gross Profit

184.2

189.2

-2.6%

Non-GAAP Gross Profit

186.1

191.4

-2.8%

Operating Income

50.0

64.4

-22.4%

Non-GAAP Operating Income

59.3

71.6

-17.3%

EBITDA

64.8

77.0

-15.8%

Net Income[1]

41.2

59.6

-31.0%

Non-GAAP Net Income[1]

49.5

66.2

-25.3%

Non-GAAP Net Income (ex tax benefit) [2]

49.5

64.3

-23.0%

Diluted EPS

0.35

0.50

-31.3%

Non-GAAP Diluted EPS

0.42

0.56

-25.6%

Non-GAAP Diluted EPS (ex tax benefit)

0.42

0.54

-23.3%


[1] For this press release, net income and non-GAAP net income refers to GAAP net income attributable to the company and Non-GAAP net income attributable to the company as stated in exhibit below, respectively.


[2] The non-GAAP net income (ex tax benefit) excludes the tax benefits of $2.0 million recognized in the second quarter of 2014 in relation to the nationwide key software enterprise status. Such status is reviewed by the Chinese government every two years and is subject to approval. The company did not record any such tax benefit in the second quarter of 2015.

Net Revenues

Mindray reported net revenues of $336.8 million for the second quarter of 2015, a 0.7% increase from the second quarter of 2014.

  • Net revenues generated in China increased 0.9% year-over-year to $153.9 million.
  • Net revenues generated in the international markets increased 0.5% year-over-year to $183.0 million.

Performance by Segment

Patient Monitoring & Life Support Products: Net revenues in this segment decreased 8.1% from the second quarter of 2014 to $109.7 million, contributing 32.6% to total net revenues in the second quarter of 2015.

In-Vitro Diagnostic Products: Net revenues in this segment increased 6.3% year-over-year to $104.5 million, contributing 31.0% to total net revenues in the second quarter of 2015. Reagents sales represented 48.8% of net revenues in this segment.

Medical Imaging Systems: Net revenues in this segment increased 4.4% from a year ago to $88.3 million, contributing 26.2% to total net revenues in the second quarter of 2015.

Others: Net revenues increased 6.4% to $34.3 million from the second quarter of 2014, contributing 10.2% to total net revenues in the second quarter of 2015. Other net revenues mainly include sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period.

Gross Margin

Second quarter 2015 gross profit was $184.2 million, a 2.6% decrease from the second quarter of 2014. Gross margin was 54.7% in the second quarter of 2015 compared to 56.6% in the second quarter of 2014 and 54.6% in the first quarter of 2015. Second quarter 2015 non-GAAP gross profit was $186.1 million, a 2.8% decrease from the second quarter of 2014. Non-GAAP gross margin was 55.2% in the second quarter of 2015 compared to 57.2% in the second quarter of 2014 and 55.4% in the first quarter of 2015.

Operating Expenses 

Selling expenses for the second quarter of 2015 were $63.9 million, or 19.0% of total net revenues, unchanged from the second quarter of 2014 and compared to 20.7% in the first quarter of 2015. Non-GAAP selling expenses for the second quarter of 2015 were $60.9 million, or 18.1% of total net revenues, unchanged from the second quarter of 2014 and compared to 19.7% in the first quarter of 2015.

General and administrative expenses for the second quarter of 2015 were $34.0 million, or 10.1% of total net revenues, compared to 8.2% in the second quarter of 2014 and 9.9% in the first quarter of 2015. Non-GAAP general and administrative expenses for the second quarter of 2015 were $30.8 million, or 9.1% of total net revenues, compared to 8.0% in the second quarter of 2014 and 9.2% in the first quarter of 2015.

Research and development expenses for the second quarter of 2015 were $36.4 million, or 10.8% of total net revenues, compared to 10.1% in the second quarter of 2014 and 12.7% in the first quarter of 2015. Non-GAAP research and development expenses for the second quarter of 2015 were $35.1 million, or 10.4% of total net revenues, compared to 9.7% in the second quarter of 2014 and 12.2% in the first quarter of 2015.

Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $3.7 million in the second quarter of 2015 compared to $3.8 million in the second quarter of 2014 and $3.6 million in the first quarter of 2015.

Operating Income

Operating income for the second quarter of 2015 was $50.0 million, a 22.4% decrease from a year ago. Operating margin was 14.8% in the second quarter of 2015 compared to 19.3% in the second quarter of 2014 and 11.4% in the first quarter of 2015. Non-GAAP operating income for the second quarter of 2015 was $59.3 million, a 17.3% decrease from the second quarter of 2014. Non-GAAP operating margin was 17.6% in the second quarter of 2015 compared to 21.4% in the second quarter of 2014 and 14.3% in the first quarter of 2015.

Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")

Second quarter 2015 EBITDA decreased 15.8% year-over-year to $64.8 million.

Net Income

Second quarter 2015 net income decreased 31.0% year-over-year to $41.2 million. Net margin was 12.2% in the second quarter of 2015 compared to 17.8% in the second quarter of 2014 and 11.8% in the first quarter of 2015. Second quarter 2015 non-GAAP net income decreased 25.3% year-over-year to $49.5 million. Non-GAAP net margin was 14.7% in the second quarter of 2015, compared to 19.8% in the second quarter of 2014 and 14.5% in the first quarter of 2015. Second quarter 2015 interest income was $3.0 million, down from $7.7 million a year ago and $11.3 million in the previous quarter. In the second quarter of 2015, the company recorded a $7.6 million interest receivable provision based on the uncertainty of interest payment from certain short-term investments (where the principal amount is guaranteed but not the interest portion). Second quarter 2015 income tax expense was $10.2 million, representing an effective tax rate of 19.2%.  

Second quarter 2015 non-GAAP net income (excluding the tax benefits in relation to our nationwide key software enterprise status) decreased 23.0% year-over-year to $49.5 million. Non-GAAP net margin (excluding the tax benefits in relation to our nationwide key software enterprise status) was 14.7% in the second quarter of 2015, compared to 19.2% in the second quarter of 2014 and 14.5% in the first quarter of 2015.

Second quarter 2015 basic and diluted earnings per share were both $0.35, compared to $0.51 and $0.50 respectively in the second quarter of 2014. Second quarter basic and diluted non-GAAP earnings per share were both $0.42, compared to $0.57 and $0.56 respectively in the second quarter of 2014. Shares used in the computation of basic and diluted earnings per share for the second quarter of 2015 were approximately 117.8 million and 118.7 million, respectively.

Other Select Data

Accounts receivable turnover days were 51 days in the second quarter of 2015, compared to 52 days a year ago and lower than 68 days in the first quarter of 2015. Inventory turnover days were 101 days in the second quarter of 2015, compared to 99 days in the second quarter of 2014 and 116 days in the first quarter of 2015. Accounts payable turnover days were 57 days in the second quarter of 2015, compared to 62 days in the second quarter of 2014 and 72 days in the first quarter of 2015. Mindray calculates the above working capital turnover days using the average of the beginning and ending net balances of the quarter.

As of June 30, 2015, the company had a total of $1,057.9 million in cash and cash equivalents, as well as short-term and restricted investments, compared to $1,104.7 million as of March 31, 2015. Net cash generated from operating activities and net cash outflow for capital expenditures for the second quarter of 2015 were $62.1 million and $20.3 million respectively.

As of June 30, 2015, the company had over 8,200 employees.

Business Outlook for Full Year 2015

Mindray now expects its full year 2015 net revenues to grow by a low-single-digit percentage over its full year 2014 net revenues.

Mindray has revised its full year 2015 non-GAAP net income and now expects it to decrease by around 30% over its full year 2014 non-GAAP net income. This revision is due to lower revenue guidance and lower interest income. The non-GAAP net income guidance continues to assume the 2015 payments related to the recently announced employee incentive and talent retention program will be distributed half in equity based compensation and half in cash. Please note, however, that this assumption is subject to change and the exact impact will depend on the actual split between equity based compensation and cash payments. The company will provide more updates as additional details of the program are finalized. The non-GAAP net income guidance also excludes the tax benefits related to the nationwide key software enterprise status and projects a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.

The company expects its capital expenditure for full year 2015 to be around $150 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

"Although the near-term outlook of our overall business remains challenging amid a difficult environment, we are working diligently to strengthen our competitive position and seize business opportunities," commented Mr. Cheng Minghe, Mindray's Co-Chief Executive Officer and Chief Strategic Officer. "Our goal is to build a stronger foundation for sustainable future growth. We will continue to invest prudently into our global sales, marketing, and distribution networks, as well as product development capabilities. We will continue to pursue attractive M&As and other partnerships opportunities to ensure the future success of Mindray."

Conference Call Information

Mindray's management will hold an earnings conference call at 8:00 AM on August 11, 2015 U.S. Eastern Time (8:00 PM on August 11, 2015 Beijing/Hong Kong Time).

Dial-in details for the earnings conference call are as follows:

International Toll Free:


United States:

+1-866-519-4004

United Kingdom:

080-8234-6646

Hong Kong:

800-906-601

China Landline:

800-819-0121

Local dial-in numbers:

United States:

+1-845-675-0437

United Kingdom:

+44-20-3059-8139

Hong Kong:

+852-3018-6771

China Mobile:

400-620-8038

Passcode for all regions:

Mindray

A replay of the conference call may be accessed by phone at the following numbers until August 26, 2015.

U.S. Toll Free:

+1-855-452-5696

International:

+1-646-254-3697

Passcode:

81850811

Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at: http://ir.mindray.com/.

Use of Non-GAAP Financial Measures

Mindray provides gross profit, selling expenses, general and administrative expenses, research and development expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense, acquired intangible assets amortization expense and dispute related legal fees, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance for the second quarter of 2015. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

The company has reported for the second quarter of 2015 and its comparative periods on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, amortization of acquired intangible assets and dispute related legal fees.
  • Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation and dispute related legal fees.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation, amortization of acquired intangible assets and dispute related legal fees, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, income tax provision, depreciation and amortization.

The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three and six months ended June 30, 2014 and 2015, respectively, in the attached financial information.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2015, our expected lower interest income for 2015, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, our anticipated uncertainty of interest payment from certain short-term investments (where the principal amount is guaranteed but not the interest portion) in relation to $7.6 million interest receivable provision recorded by us in this second quarter of 2015, our continued assumption of the 2015 payments related to the recently announced employee incentive and talent retention program to be distributed half in equity based compensation and half in cash, statements that the exact impact of the assumption of the 2015 payments related to the recently announced employee incentive and talent retention program will depend on the actual split between equity based compensation and cash payments, that although the near-term outlook of our overall business remains challenging amid a difficult environment, we are working diligently to strengthen our competitive position and seize business opportunities, that we will continue to invest prudently into our global sales, marketing, and distribution networks, as well as product development capabilities, that we will continue to pursue attractive M&As and other partnerships opportunities to ensure the future success of Mindray and other statements under "Business Outlook for full year 2015" are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, competitive, pricing and other conditions in China and our international markets and our ability to effectively address or respond those conditions; our ability effectively attract and retain our key employees; the growth and expected growth of the medical device market in China and internationally; applicable government policies and regulations; our ability to satisfy the requirements imposed by relevant regulatory bodies;  market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 6 of our annual report on Form 20-F, which was filed, with the Securities and Exchange Commission on April 16, 2015. Our results of operations for the second quarter of 2015 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

For investor and media inquiries, please contact:

In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com

In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com  

 

Exhibit 1

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands of US dollars)








As of  December 31, 2014


As of  June 30, 2015



 US$ 


 US$ 



 (Note 1) 


 (unaudited) 

ASSETS




Current assets:





Cash and cash equivalents (Note 2)

276,598


284,194


Restricted cash (Note 3)

7,422


10,683


Restricted investments (Note 4)

-


244,128


Short-term investments (Note 2)

816,394


529,544


Accounts receivable, net

222,522


188,485


Inventories

150,642


172,785


Value added tax receivables

3,432


11,398


Other receivables and current assets

23,316


105,184


Prepayments and deposits

16,481


18,976


Deferred tax assets,net

14,802


17,957

Total current assets

1,531,609


1,583,334






Restricted cash, non-current (Note 3)

5,061


2,784

Other assets

9,666


9,605

Accounts receivables, net, non-current

3,350


2,566

Advances for purchase of plant and equipment

21,840


19,725

Property, plant and equipment, net

412,733


438,624

Land use rights, net 

59,057


58,414

Intangible assets, net

175,451


165,612

Goodwill

254,435


254,510

Total assets

2,473,202


2,535,174






LIABILITIES AND EQUITY




Current liabilities:





Short-term bank loans

59,625


129,115


Notes payable

9,234


8,211


Accounts payable

93,523


90,720


Advances from customers

31,396


52,266


Salaries payable

114,583


79,924


Other payables and current liabilities

168,139


168,825


Purchase consideration payable

17,173


11,592


Income taxes payable

20,415


23,405


Other taxes payable

10,342


6,354

Total current liabilities

524,430


570,412






Long-term bank loans

197,585


168,000

Other long-term liabilities

10,670


11,280

Deferred tax liabilities, net

69,233


74,574

Total liabilities

801,918


824,266






Mindray shareholders' equity:




Ordinary shares

15


15

Additional paid-in capital

453,564


462,765

Retained earnings

1,000,257


1,026,495

Accumulated other comprehensive income

144,120


145,158

Treasury stock at cost

-


-

Total Mindray shareholders' equity

1,597,956


1,634,433






Non-controlling interests

73,328


76,475

Total equity

1,671,284


1,710,908

Total liabilities and equity

2,473,202


2,535,174






(1) Financial information is extracted from the audited financial statements included in the Company's 2014 annual report on Form 20-F.


(2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of $189,000 and $nil as of December 31, 2014 and June 30, 2015, respectively in relation to the drawings of certain bank loans.


(3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.


(4) Restricted investments are those investments in Chinese Renminbi denominated financial products placed with bank which are restricted as to withdrawal or usage according to new terms imposed on certain bank loans during the quarter ended March 31, 2015.

 

Exhibit 2

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of US dollars, except share and per share amounts)












   Three months ended June 30,


   Six months ended June 30,



2014


2015


2014


2015



US$


 US$ 


US$


 US$ 



(unaudited)


 (unaudited) 


(unaudited)


 (unaudited) 

Net revenues









- China


152,469


153,864


268,297


275,821

- International 


181,983


182,953


330,926


333,460

Net revenues


334,452


336,817


599,223


609,281

Cost of revenues 


(145,237)


(152,584)


(263,988)


(276,213)

Gross profit


189,215


184,233


335,235


333,068










Selling expenses 


(63,471)


(63,860)


(118,267)


(120,318)

General and administrative expenses 


(27,578)


(33,993)


(57,391)


(60,946)

Research and development expenses 


(33,724)


(36,403)


(63,867)


(70,889)

Income from operations


64,442


49,977


95,710


80,915










Other (expenses) income, net


(215)


908


1,594


1,793

Interest income


7,678


3,048


18,457


14,330

Interest expense


(1,291)


(1,108)


(3,686)


(2,093)

Income before income taxes and non-controlling interests


70,614


52,825


112,075


94,945

Income tax provision


(9,448)


(10,157)


(13,948)


(18,463)

Net income 


61,166


42,668


98,127


76,482

Less: Net income attributable to non-controlling interests


(1,548)


(1,507)


(2,871)


(3,147)

Net income attributable to Mindray shareholders


59,618


41,161


95,256


73,335










Basic earnings per share


0.51


0.35


0.81


0.62










Diluted earnings per share


0.50


0.35


0.81


0.62










Shares used in the computation of:









Basic earnings per share


116,974,009


117,831,719


116,914,653


117,823,198










Diluted earnings per share


118,132,930


118,700,403


118,313,540


118,809,042

 

 

Exhibit 3

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of US dollars)












   Three months ended June 30,


   Six months ended June 30,



2014


2015


2014


2015



 US$ 


 US$ 


 US$ 


 US$ 



 (unaudited) 


 (unaudited) 


 (unaudited) 


 (unaudited) 

Cash flow from operating activities:









  Net income

61,166


42,668


98,127


76,482


  Adjustments to reconcile net income to net cash provided by operating activities

20,833


31,524


48,697


55,382


  Changes in assets and liabilities, net of effects of acquisitions

2,600


(12,107)


(42,559)


(32,787)

Net cash provided by operating activities 

84,599


62,085


104,265


99,077










Cash flow from investing activities:









   Acquisition cost of subsidiaries, net of cash received 

(6,009)


(3,071)


(8,215)


(5,578)


   Capital expenditures

(23,176)


(20,316)


(51,051)


(51,096)


   Decrease (Increase) in restricted cash and restricted investments 

4,941


-


(1,514)


(53,114)


   Proceeds from sale of short-term investments

374,551


142,794


616,515


152,571


   Increase in short-term investments and changes in other investing activities

(328,773)


(115,798)


(341,738)


(132,181)

Net cash provided by (used in) investing activities

21,534


3,609


213,997


(89,398)










Cash flow from financing activities:









   Repayment of bank loans

(160,000)


(4,375)


(210,000)


(4,375)


   Proceeds from bank loans, net of costs

-


-


-


47,712


   Dividend paid

-


-


(58,711)


(47,097)


   Proceeds from exercise of options

669


242


1,014


1,857


   Repurchase of ordinary American depositary shares

(51)


-


(68,080)


-


   Cash paid to acquire a non-controlling interest

(4,286)


-


(4,731)


-


   Cash contribution from a non-controlling interest

-


-


239


-

Net cash used in financing activities

(163,668)


(4,133)


(340,269)


(1,903)










Net (decrease) increase in cash and cash equivalents

(57,535)


61,561


(22,007)


7,776


Cash and cash equivalents, beginning of period

419,820


221,699


385,224


276,598


Effect of exchange rate changes on cash and cash equivalents

26


934


(906)


(180)

Cash and cash equivalents, end of period

362,311


284,194


362,311


284,194

 

 

Exhibit 4

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST
COMPARABLE GAAP MEASURES

(In thousands of US dollars, except share and per share amounts)












   Three months ended June 30,


   Six months ended June 30,



2014


2015


2014


2015



(unaudited)


(unaudited)


(unaudited)


(unaudited)



 US$ 


 US$ 


 US$ 


 US$ 

Non-GAAP net income attributable to Mindray shareholders


66,219


49,496


112,273


88,953

Non-GAAP net margin


19.8%


14.7%


18.7%


14.6%

Amortization of acquired intangible assets


(3,438)


(3,314)


(6,885)


(6,692)

Deferred tax impact related to acquired intangible assets


604


617


1,219


1,235

Dispute related legal fees, net of related tax impact


-


(1,900)


-


(2,819)

Share-based compensation


(3,767)


(3,738)


(11,351)


(7,342)

GAAP net income attributable to Mindray shareholders


59,618


41,161


95,256


73,335

GAAP net margin


17.8%


12.2%


15.9%


12.0%










Non-GAAP basic earnings per share


0.57


0.42


0.96


0.75

Non-GAAP diluted earnings per share


0.56


0.42


0.95


0.75










GAAP basic earnings per share


0.51


0.35


0.81


0.62

GAAP diluted earnings per share


0.50


0.35


0.81


0.62










 Shares used in computation of: 









 Basic earnings per share 


116,974,009


117,831,719


116,914,653


117,823,198

 Diluted earnings per share 


118,132,930


118,700,403


118,313,540


118,809,042










Non-GAAP operating income


71,647


59,264


113,946


98,266

Non-GAAP operating margin


21.4%


17.6%


19.0%


16.1%

Amortization of acquired intangible assets


(3,438)


(3,314)


(6,885)


(6,692)

Dispute related legal fees


-


(2,235)


-


(3,317)

Share-based compensation


(3,767)


(3,738)


(11,351)


(7,342)

GAAP operating income


64,442


49,977


95,710


80,915

GAAP operating margin


19.3%


14.8%


16.0%


13.3%










Non-GAAP gross profit


191,414


186,050


339,538


336,969

Non-GAAP gross margin


57.2%


55.2%


56.7%


55.3%

Amortization of acquired intangible assets 


(1,937)


(1,724)


(3,868)


(3,514)

Share-based compensation


(262)


(93)


(435)


(387)

GAAP gross profit


189,215


184,233


335,235


333,068

GAAP gross margin


56.6%


54.7%


55.9%


54.7%










Non-GAAP selling expenses


(60,585)


(60,908)


(112,759)


(114,467)

Non-GAAP as % of total net revenues


18.1%


18.1%


18.8%


18.8%

Amortization of acquired intangible assets 


(1,501)


(1,590)


(3,017)


(3,178)

Share-based compensation


(1,385)


(1,362)


(2,491)


(2,673)

GAAP selling expenses


(63,471)


(63,860)


(118,267)


(120,318)

GAAP as % of total net revenues


19.0%


19.0%


19.7%


19.7%










Non-GAAP general and administrative expenses


(26,844)


(30,761)


(51,406)


(55,858)

Non-GAAP as % of total net revenues


8.0%


9.1%


8.6%


9.2%

Dispute related legal fees


-


(2,235)


-


(3,317)

Share-based compensation


(734)


(997)


(5,985)


(1,771)

GAAP general and administrative expenses


(27,578)


(33,993)


(57,391)


(60,946)

GAAP as % of total net revenues


8.2%


10.1%


9.6%


10.0%










Non-GAAP research and development expenses


(32,338)


(35,117)


(61,427)


(68,378)

Non-GAAP as % of total net revenues


9.7%


10.4%


10.3%


11.2%

Share-based compensation


(1,386)


(1,286)


(2,440)


(2,511)

GAAP research and development expenses


(33,724)


(36,403)


(63,867)


(70,889)

GAAP as % of total net revenues


10.1%


10.8%


10.7%


11.6%

 

Exhibit 5

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION
AND AMORTIZATION

(In thousands of US dollars)














   Three months ended June 30,


   Six months ended June 30,




2014


2015


2014


2015




US$


US$


US$


US$




(unaudited)


(unaudited)


(unaudited)


(unaudited)

GAAP net income attributable to the Company


59,618


41,161


95,256


73,335


Interest income


(7,678)


(3,048)


(18,457)


(14,330)


Interest expense


1,291


1,108


3,686


2,093


Income tax provision


9,448


10,157


13,948


18,463











Earnings before interest and taxes ("EBIT")


62,679


49,378


94,433


79,561


Depreciation


8,704


9,949


17,332


19,771


Amortization


5,567


5,452


11,146


10,970











Earnings before interest, taxes, depreciation, and amortization ("EBITDA")


76,950


64,779


122,911


110,302

SOURCE Mindray Medical International Limited



RELATED LINKS

http://ir.mindray.com